BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 16261260)

  • 1. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
    Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
    Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
    Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
    Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hutchinson-Gilford progeria syndrome through the lens of transcription.
    Prokocimer M; Barkan R; Gruenbaum Y
    Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
    Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
    Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
    Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
    Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
    McClintock D; Gordon LB; Djabali K
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
    Eisch V; Lu X; Gabriel D; Djabali K
    Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A conserved splicing mechanism of the LMNA gene controls premature aging.
    Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
    Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): Current trends and future perspectives for drug discovery.
    Lo Cicero A; Nissan X
    Ageing Res Rev; 2015 Nov; 24(Pt B):343-8. PubMed ID: 26474742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
    Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
    FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
    Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
    BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Roedl D; Gordon LB; Djabali K
    Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers.
    Delbarre E; Tramier M; Coppey-Moisan M; Gaillard C; Courvalin JC; Buendia B
    Hum Mol Genet; 2006 Apr; 15(7):1113-22. PubMed ID: 16481358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progeria, the nucleolus and farnesyltransferase inhibitors.
    Mehta IS; Bridger JM; Kill IR
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
    Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
    Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.